Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation

NCT00587288 is registered in ClinicalTrials.gov with Ception Therapeutics as lead sponsor.

NCT NCT00587288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00587288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation
Lead sponsor
Ception Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
March 31, 2010
Enrollment
106 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

asthma